The Longest Review: Inside Ovation’s Wait For Sabril

The anticonvulsant vigabatrin is one of a dozen products for which FDA has missed user fee deadlines so far this year. Fifteen years after the NDA first was submitted, maybe that shouldn’t be a surprise.